Pano Therapeautics
1 known investors
Find your way into Pano Therapeautics
Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.
Founders & leadership
Investors · 1
Competitors · 2
by search overlap
Palvellatx5 shared keywordsPalvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
Neurona Therapeutics4 shared keywordsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
Companies competing with Pano Therapeautics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Pano Therapeautics do?
- Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.
- Who founded Pano Therapeautics?
- Pano Therapeautics was founded by Ben Gibson, Ken Batchelor.
- Who are Pano Therapeautics's investors?
- Pano Therapeautics's investors include Western Technology Investment.